,trastuzumab deruxtecan
Daiichi Sankyo,astrazeneca
['enhertu', 'daiichi']
engaging in a great conversation with pharma. #asco2022 #enhertu #daiichisankyo of course i had to mention i was on the destiny trial and that they need to have more diversity in trials. we talked for a good while. 
11 Year MBC HER 2+ Breast Cancer Survivor.  Bringing racial disparities and clinical trials to the conversation. 25 YR AF Veteran.  BA/MBA Komen Scholar